Information regarding Phase III clinical trials for retatrutide for weight loss presents a notable divergence in available data. While several AI assistants identify multiple completed and ongoing Phase III trials for retatrutide, our specific research corpus indicates a lack of direct information on retatrutide’s Phase III trials, instead providing general context from other weight loss drugs like liraglutide.
What the AI Assistants Say
Collectively, AI assistants describe retatrutide as an investigational drug developed by Eli Lilly, functioning as a first-in-class triple agonist of the GLP-1, GIP, and glucagon receptors. This unique mechanism is hypothesized to lead to greater weight loss by simultaneously increasing satiety, slowing gastric emptying, improving glucose control, and, notably, boosting energy expenditure and lipolysis through glucagon agonism.
Regarding Phase III trials, the assistants generally agree that a comprehensive program is underway or largely complete, though they differ on the specific program name. Some refer to it as the “TRIUMPH” program, while others call it “SURMOUNT.”
Agreements:
- Key Completed/Reported Trials: TRIUMPH-1 (or SURMOUNT-1), described as the pivotal general obesity trial, and TRIUMPH-4 (or SURMOUNT-4), often specified for populations including knee osteoarthritis, are consistently cited as having completed or announced topline results.
- Ongoing Trials: Trials like TRIUMPH-2 (for obesity with Type 2 Diabetes) and TRIUMPH-3 (for Class II/III obesity with cardiovascular disease) are mentioned as ongoing, with others potentially addressing obstructive sleep apnea and long-term outcomes.
- Significant Weight Loss: The assistants consistently report substantial mean weight loss in these trials. For example, TRIUMPH-1/SURMOUNT-1 is cited with mean weight reductions ranging from approximately 19.0% to 28.3% at various doses (4 mg, 9 mg, 12 mg) over 80 weeks, with the highest doses approaching or exceeding 28%. TRIUMPH-4 also reported mean weight loss up to 28.7% at 12 mg over 68 weeks in treated participants.
- Common Adverse Events: Gastrointestinal issues such as nausea, diarrhea, vomiting, and constipation are commonly listed as the most frequent adverse events.
Differences:
- Program Name: The Phase III program is referred to as “TRIUMPH” by some assistants and “SURMOUNT” by others.
- Trial Status and Timelines: While general agreement exists on completed and ongoing trials, specific publication or announcement dates provided by assistants vary (e.g., December 2025, May 2026, June 2026 for results, versus “late 2023 and early 2024” for topline announcements).
- Phase Designation Clarity: One assistant indicates that the widely cited initial study (SURMOUNT-1) was technically a Phase 2 study, despite its robust design and results, while others clearly classify TRIUMPH-1 as a pivotal Phase III trial.
- Specific Details: While consistent in overall findings, exact weight loss percentages and participant numbers can vary slightly across the assistants’ summaries for the same trials. One assistant also specifically mentions a planned head-to-head Phase III trial comparing retatrutide with tirzepatide.
What the Research Actually Shows
Based on the provided research corpus, there is no specific information provided about Phase III clinical trials conducted to evaluate the efficacy of retatrutide for weight loss.
However, the sources do offer insights into Phase III clinical trials related to weight loss drugs in general, using liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, as a reference point for understanding the clinical trial process for weight loss drugs.
- In the context of Phase III clinical trials for weight loss drugs, one source [2] discusses the efficacy and safety of liraglutide 3.0 mg daily injections for weight loss in overweight/obese patients. The largest trial mentioned was a 56-week study with a 104-week extension for patients with prediabetes at baseline.
- This trial randomized 3731 overweight/obese patients without type 1 or type 2 diabetes (61% had prediabetes) in a 2:1 ratio to receive daily liraglutide 3.0 mg or placebo injections [84•].
- At 56 weeks, the mean weight change with liraglutide was −8.0% compared to −2.6% with placebo. This trial serves as an example of the scale and design typical for a Phase III clinical trial for a weight loss drug.
- Another source [4] describes a 56-week, randomized, placebo-controlled trial evaluating the efficacy and safety of 3.0 mg of liraglutide, injected subcutaneously once daily, as an adjunct to a reduced-calorie diet and increased physical activity, for weight management in overweight or obese adults who did not have diabetes at baseline. This trial was conducted across various global locations and involved a large number of patients, consistent with the characteristics of Phase III trials.
- Generally, Phase III clinical trials are expanded controlled and uncontrolled trials performed after preliminary data on effectiveness are obtained [5]. These studies aim to gather additional information about product effectiveness and safety to assess the overall benefit-risk relationship and provide a basis for physician labeling. Phase III studies typically include several hundred to several thousand patients, depending on the clinical indication and patient population.
In summary, while the provided research corpus lacks direct information on retatrutide’s Phase III trials, it outlines the typical design, scale, and objectives of such trials through the example of liraglutide.
Where the AI Consensus and the Research Diverge
There is a stark and critical divergence between the information provided by the AI assistants and the specific research corpus regarding retatrutide’s Phase III clinical trials. The AI assistants offer detailed accounts of multiple completed and ongoing Phase III trials for retatrutide, including specific names (e.g., TRIUMPH-1, TRIUMPH-4), participant numbers (e.g., 2,339 for TRIUMPH-1), durations (e.g., 80 weeks), and highly impressive weight loss percentages (e.g., up to 28.7%). This presents a clear picture of an advanced drug in late-stage clinical development with robust evidence.
In direct contrast, the provided research corpus explicitly states, “There is no specific information provided in the given sources about Phase III clinical trials conducted to evaluate the efficacy of retatrutide for weight loss.” Instead of providing retatrutide-specific data, the corpus describes general characteristics of Phase III trials and uses liraglutide as an example, reporting a mean weight loss of −8.0% at 56 weeks. This fundamental discrepancy indicates that the AI assistants are drawing from a knowledge base that includes more recent or extensive information about retatrutide’s clinical development than what is contained within the specific research corpus provided for this task.
Bottom line: While AI assistants describe multiple Phase III trials showing significant weight loss for retatrutide, the provided research corpus explicitly states a lack of specific information on retatrutide’s Phase III trials, instead detailing examples from other weight loss drugs.
References
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- Antimicrobial Peptides_ Basics for Clinical Application
- Clinical Trials in Dermatology
- Contemporary Endocrinology_ Leptin
- Dermatology_ A Pictorial Review
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss_ Systematic Review and Meta-Analyses of Randomised C
- GHRH, GH, and IGF-1_ Basic and Clinical Advances
- Gene and Cell Therapy_ Therapeutic Mechanisms and Strategies
- Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes
- Goodman and Gilman's The Pharmacological Basis of Therapeutics
- Peptide Protocols Volume One — William A Seeds MD
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Peptides_ Chemistry and Biology, 2nd Edition
- Pharmacotherapy of obesity_ clinical trials to clinical practice
- Principles and Practice of the Biologic Therapy of Cancer
- The neuroendocrine control of energy storage
- Tumor Suppressor Genes_ Volume 2_ Regulation, Function, and Medicinal Applications
Continue your research
Part of our Retatrutide: Research Evidence & Trials guide.
- What clinical trials provide evidence for the efficacy and safety of retatrutide in weight management?
- What preclinical studies have been conducted to explore the potential benefits of retatrutide?
- What real-world evidence is available regarding the effectiveness of retatrutide in weight loss management?
Related topics:
- How does retatrutide compare to other weight loss medications in terms of efficacy and side effects?
- What cardiovascular benefits have been associated with the use of retatrutide in clinical studies?
- How does the efficacy of retatrutide compare with that of other anti-obesity drugs in terms of weight loss and maintenance?